(15008931), J. S. W., (15054769), H. T., (15054772), J. A. E., (15054775), N. M. A., (15054778), B. S., (15054781), H. B., . . . (14932995), M. A. D. (2025). Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Dyfyniad Arddull Chicago(15008931), James S. Wilmott, et al. Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib Plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. 2025.
Dyfyniad MLA(15008931), James S. Wilmott, et al. Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib Plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. 2025.